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 Abstract 
 Background/Aims: A 33-year-old man was referred for the 
first time to the Division of Neurology because of the pres-
ence and progression of neurological symptoms. Dyspha-
gia, weakness, reduced tear production, and nasal speech 
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 Established Facts 
 • Triple A syndrome generally manifests during childhood, mostly during the first decade.
 • Adult onset of the disease is very rare. 
• There is a risk of delayed diagnosis. 
 Novel Insights 
 • Late-onset form of triple A syndrome should be considered as possible and adult onset may be a con-
founding factor for the diagnosis, due to its rarity.
 • The diagnosis of triple A syndrome should be checked also in adult patients with one or more clinical 
signs and symptoms of the disease. 
 • Increasing the awareness on late onset triple A syndrome among physicians may prevent overlooking 
and undermanaging the disease. 
• An adequate multidisciplinary clinical approach is advocated in these patients, especially in adult-
hood. 
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were present. In order to point the attention of late-onset 
triple A syndrome we describe this case and review the lit-
erature.  Methods: Hormonal and biochemical evaluation, 
Schirmer test, tilt test and genetic testing for  AAAS gene mu-
tations.  Results: Late-onset triple A syndrome caused by a 
novel homozygous missense mutation in the  AAAS gene 
(A167V in exon 6) was diagnosed at least 17 years after symp-
tom onset.  Conclusions: The association between typical 
signs and symptoms of triple A syndrome should suggest 
the diagnosis even if they manifest in adulthood. The diag-
nosis should be confirmed by Schirmer test, endocrine test-
ing (both basal and dynamic), genetic analysis, and detailed 
gastroenterological and neurological evaluations. Aware-
ness of the possible late onset of the disease and of diagno-
sis in adulthood is still poor among clinicians, the acquain-
tance with the disease is more common among pediatricians. 
The importance of an adequate multidisciplinary clinical ap-
proach, dynamic testing for early diagnosis of adrenal insuf-
ficiency and periodical reassessment of adrenal function are 
emphasized.  Copyright © 2008 S. Karger AG, Basel 
 Introduction 
 The association among familial glucocorticoid defi-
ciency due to ACTH insensitivity, achalasia of the cardia, 
alacrima and autonomic dysfunction was firstly de-
scribed in 1978 by Allgrove et al. [1] in two pairs of sib-
lings (aged 4–6 years). This rare condition is also called 
triple A syndrome (adrenal dysfunction/alacrima/acha-
lasia), and may be associated with autonomic nervous 
system failure, neurological disorders (autonomic failure 
and/or peripheral neuropathy, abnormal functioning of 
peripheral motor and sensory fibers), impaired cognitive 
function, mental retardation and dementia  [1, 2] .
 The linkage of the triple A syndrome locus to markers 
on chromosome 12q13 (AS; MIM No. 231550)  [2–5] , and 
the effect of mutations in the gene encoding ALADIN 
(AAAS;  * 605378) have been demonstrated. ALADIN is a 
protein that belongs to the WD tryptophane-aspartic 
acid repeat-containing protein (WD) family  [3] . The 
function of the ALADIN protein is not clear, but it could 
be shown that it is a component of the nuclear pore com-
plex (NPC) of cells  [2, 3] . The inheritance of the disease 
is autosomal recessive  [2–5] and it occurs in childhood 
with a high rate of sudden death due to acute crisis of hy-
poglycemia when the disease is not recognized  [4–8] . 
Furthermore, several reports described the occurrence of 
the syndrome in adulthood  [9–12] , and Kimber et al.  [11] 
provided interesting evidence on the existence of a sub-
group of patients with a less severe pediatric clinical pre-
sentation and course of disease.
 Here we report a case of late-onset triple A syndrome 
in an adult Italian subject with a novel mutation in the 
 AAAS gene and provide a review of the literature on late-
onset occurrence of the disease  [9–12] , paying particular 
attention to the progressive nature of the manifestations 
in adulthood. The aim is to add information to the small 
literature on delayed-onset forms and to reinforce the 
concept of a possible occurrence of the disease in adult-
hood, providing a useful reminder to the endocrine com-
munity on the difficulties in diagnosis.
 Case Report 
 A 33-year-old man was referred for the first time to the Divi-
sion of Neurology because of the presence and the progressive 
advancement of neurological symptoms in the previous 3 years 
and achalasia. The patient’s family history was uneventful from 
the viewpoint of gastroenterological, endocrinological and neu-
rological diseases. The patient’s past medical history involved 
several periods of hospitalization, without any precise diagnosis. 
Since the age of 8 years, some mild gastrointestinal symptoms 
(episodes of nausea and rare vomiting) were present, but they did 
not require medical consultation and had no significant conse-
quences for his wellbeing. At the age of 16, due to progressive dys-
phagia, nausea, vomiting and weight loss, the patient underwent 
a standard X-ray with barium contrast leading to the diagnosis of 
idiopathic mega-esophagus. The patient was treated surgically 
with extramucosal Heller’s myotomy, resulting in improved 
symptoms and an 11-year disease-free period.
 At the age of 27 years, the patient again started to complain of 
dysphagia, followed by loss of muscle strength with preferential 
distal muscular atrophy. During hospitalization in a gastroen-
terological unit, the diagnosis of achalasia was confirmed by 
means of endoscopic and manometric evaluations. Subsequent 
evaluations of fasting glucose showed a trend towards values at 
the lower end of the normal range (59, 67, 73 mg/dl) without a 
history of symptoms related to hypoglycemia; moreover, low 24-
hour urinary cortisol levels (62, normal range 92–473   g/24 h) 
were measured, together with normal serum cortisol (14   g/dl) 
and ACTH (15 pg/ml) at 8: 00 a.m. and normal values of natremia 
and kalemia. Notwithstanding these biochemical data, endocri-
nological counseling at that time excluded adrenal insufficiency 
and the absence of clinical signs did not prompt further exami-
nations.
 At the age of 30, the patient needed a further hospitalization 
in a neurological unit because of muscular weakness associated 
with rhinolalia, perioral fasciculations, atrophy and fascicula-
tions of the tongue, widespread muscular hypotrophy and weak 
Achilles tendon reflexes. Motor neuron disease was diagnosed 
based on the presence of a normal brain MRI and on electromy-
ography/electroneurography, showing both signs of mixed axo-
nal-demyelinating sensorimotor polyneuropathy and muscle de-
nervation in the limbs and bulbar musculature.
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Table 1. Anthropometric, hormonal and nutritional parameters in a 33- year-old patient with triple A syn-
drome
Normal range
Anthropometric parameters
Height, cm 170 –
Weight. kg 40 –
BMI 13.8 18.5–24.9
Total body fat (DXA), % 8.2 14–25
DXA parameters
BMD femoral neck, g/cm2 0.665 –
t-score –3.1 <2
BMD (L2–L4), g/cm2 0.994 –
t-score –1.8 <2
Total fat body mass, % 8.2 –
Total lean body mass, % 91.8 –
Hormonal measurements1
Basal serum cortisol, g/dl 14.4 5.5–25
Serum cortisol, g/dl, peak 30 min after ACTH 13.7 >18
Basal serum DHEA-S, g/ml 0.68 0.8–5.6
Serum DHEA-S, g/ml, peak 30 min after ACTH 0.7 –
Basal serum ACTH 13.2 9–52
24-hour urinary cortisol, g/24 h 47 7–152
25-OH vitamin D, ng/ml 9 11–68
Fasting insulin, mIU/ml 2.1 2.5–20
Fasting glucose, mg/dl 70 50–110
TSH, IU/l 1.42 0.35–4.5
FT3, pg/ml 3.4 1.7–4.2
FT4, pg/ml 10.6 6.1–16.7
Prolactin, ng/ml 8 2.1–17.7
LH, IU/l 4 1.4–8.9
FSH, IU/l 1.7 1.7–6.9
Testosterone, ng/dl 370 360–900
Supine/orthostatic renin, U/ml 24.3/37.9 2.4–29/3.3–41
Supine/orthostatic aldosterone, pg/ml 54.3/136.4 10–150/35–300
24-hour urinary aldosterone, g/24 h 8.8 2.8–30
Biochemical parameters1
Calcium, mEq/l 4.39 4.2–5.5
Phosphate, mg/dl 2.91 2.5–5.9
Total cholesterol, mg/dl 148 140–250
HDL-cholesterol, mg/dl 40 >45
LDL-cholesterol, mg/dl 89 0–150
Nutritional, hormonal and biochemical parameters
Triglycerides, mg/dl 66 <175
Vitamin B12, pg/ml 664 200–900
Folic acid, ng/ml 1.94 4–20
Iron, ug/dl 28 60–160
IGF-1 ng/ml 101 98–362
1 All values refer to serum concentrations except for urinary cortisol.
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 At the age of 32, a progressive bilateral sight loss became evi-
dent. Electroretinography was normal, but visual evoked poten-
tials were markedly altered bilaterally. Moreover, the patient dis-
played a history of symptomatic hypotension.
 During the last hospitalization (aged 33) the patient, seen by 
us for the first time, exhibited marked dysphagia with modest 
generalized weakness and tiredness, occurring mainly late in the 
afternoon. After specific questioning, the patient reported fre-
quent episodes of hyperhydrosis and persistently reduced tear 
production over the last few years. Poor general condition and 
malnutrition were present ( table 1 ). Physical examination showed 
facial characteristics of triple A syndrome: elongated face, narrow 
upper lip, nasal speech, bilateral pectus carinatum with central 
cavus and scoliosis, atrophy of the tongue, and enamel hypoplasia 
of the teeth. The muscles were atrophic, especially the lower and 
upper limb muscles.
 On the basis of both the clinical and medical history, the di-
agnosis of triple A syndrome suggested itself and the patient un-
derwent endocrine/metabolic, neurological and genetic evalua-
tions.
 Results 
 The neurological examination showed a worsening of 
some preexisting signs, together with dysphonia, distal 
dysesthesia and hyperesthesia in lower limbs, weak Achil-
les tendon reflexes with other deep tendon reflexes being 
brisk, spastic gait, and bilateral atrophy of the optic discs. 
Somatosensory evoked potentials were normal.
 The examination of autonomic nervous system reflex-
es indicated the involvement of the sympathetic nervous 
system; the tilt test showed evident orthostatic hypoten-
sion with acrocyanosis and a compensatory increase in 
heart rate.
 The Schirmer test disclosed severe bilateral hypolac-
rima.
 Endocrinological examinations revealed that the bas-
al serum levels of ACTH, cortisol, and 24-hour urinary 
cortisol were within the normal range, but 30 min after a 
250-  g i.v. bolus of ACTH 1–24 Cosyntropin (Cortrosyn  , 
Organon, West Orange, N.J., USA) the cortisol levels 
failed to rise above the normal 18   g/dl cutoff ( table 1 ), 
leading to the diagnosis of adrenal insufficiency. Hypo-
natriemia and hyperkalemia were absent. Basal supine 
serum renin and aldosterone were normal and both in-
creased during orthostatism. 24-hour urinary aldoste-
rone was at the lower end of the normal range. Moreover, 
a CT scan of the abdomen revealed a pattern of mild bi-
lateral hypoplasia of the adrenal glands. No other endo-
crinological abnormalities were present ( table 1 ). Meta-
bolic evaluation showed that the patient was severely un-
derweight (40 kg) with a BMI of 13.8 kg/m 2 . Total body 
fat measured by DXA (Lunar DPX-L  , Lunar Corp., Mad-
ison, Wisc., USA) was very low (8.2% of the total body 
composition;  table 1 ). Femoral osteoporosis was diag-
nosed on the basis of reduced bone mineral density, while 
osteopenia was seen at the lumbar level (L2–L4;  table 1 ). 
A slight normocytic anemia with serum folate, iron, vi-
tamin D and IGF-1 below the normal ranges, and a trend 
towards lower levels (although within normal ranges) of 
fasting serum glucose, triglycerides and serum insulin 
( table 1 ) were all most likely due to both dysphagia-re-
lated malnutrition and achalasia-related malabsorption.
 The DNA analysis allowed us to identify a novel ho-
mozygous C 1 T transition at bp 500 in exon 6 of the  AAAS 
gene resulting in a change of alanine at amino acid posi-
tion 167 into valine of the ALADIN protein (p.Ala167Val; 
 table 2 ;  fig. 1 ). As expected, the parents and the healthy 
brother were heterozygous carriers for this mutation 
( fig. 1 ). The mutation in the transfected HeLa cells re-
sulted in a GFP-ALADIN A167V protein being mislocal-
ized from the NPC to the cytoplasm ( fig. 2 ). Differences 
in the species-specific ALADIN protein sequences com-
pared to the human protein were detected and are sum-
marized in  figure 3 . Percentages demonstrate homology 
to the WD-repeat motif and homology of the entire ami-
no acid sequence compared to the human ALADIN pro-
tein ( fig. 3 ).
 Discussion 
 Diagnosis 
 The association between familial glucocorticoid defi-
ciency, achalasia of the cardia and alacrima was described 
for the first time in 1978 by Allgrove et al.  [1] . This rare 
condition is now commonly known as triple A syndrome 
(adrenal dysfunction/alacrima/achalasia) and the link-
age of the triple A syndrome locus to markers on chromo-
some 12q13 (AS; MIM No. 231550)  [2] is well known. The 
inheritance of the disease is autosomal recessive  [2–5] 
and the disease generally manifests during childhood, 
mostly during the first decade  [6] . The mean age at onset 
and diagnosis is about 6–8 years or less  [2, 7, 8] , the high 
rate of sudden deaths being due to acute crises of hypo-
glycemia when the disease is not recognized  [4–6] . How-
ever, clinical features may uncommonly manifest over a 
variable period of time  [3–7] and the adult onset of the 
disease is rare. As reviewed here, only 8 cases of triple A 
syndrome have been diagnosed during adulthood  [4, 9–
12] , some of which in late adolescence  [4, 9–12] ( table 2 ); 
only a small number of these had the diagnosis confirmed 
 Salmaggi et al.
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by a detailed molecular genetic analysis  [4, 10, 11] , with 
the diagnosis often only inferred from clinical features  [9, 
12] ( table 2 ).
 The pathophysiological basis of triple A syndrome is 
poorly understood and the progressive involvement of 
several organs and systems hinders the understanding of 
the natural history of the disease. The first step in the de-
velopment of the disease is a mutation in the gene encod-
ing ALADIN ( AAAS ;  * 605378)  [2] , a protein belonging to 
the WD family  [3] . The function of the ALADIN protein 
is not clear, but it can be shown that it is a component of 
the NPC of cells  [13] . NPCs are involved in cell growth 
and differentiation and are crucial sites for macromole-
cule translocation between the nucleus and the cytoplasm 
 [13] . Normally, wild-type ALADIN is located to the NPCs, 
while mutated proteins that induce triple A syndrome are 
mislocalized to the cytoplasm  [13] .   The wide spectrum of 
clinical features in subjects with triple A mutations re-
flects the complex function (cell division control, signal 
transduction, RNA processing, cytoskeleton assembly, 
vesicular trafficking and protein interactions) of ALA-
DIN  [13] . Since Alanine 167 is highly conserved among 
species ( fig. 3 ) and is located in a motif responsible for   -
sheet folding of the WD the mutation observed in this 
C.500C>T  (p.Ala167Val) 
Control 
 Fig. 1.  AAAS mutation in the index patient with triple A syndrome. Sequence chromatograms of the patient, 
his healthy brother and parents compared with the respective wild-type (control) sequence. The arrow indicates 
the nucleotide altered by the mutation that occurred at C.500C 1 T in exon 6 of the  AAAS gene (GenBank ac-
cession No. NH_015665). The DNA analysis was performed in accordance with standard protocols, as previ-
ously reported  [3] . The nomenclature follows den Dunnen (http://www.hgvs.org/mutnomen/). 
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patient suggests that this residue might be important for 
the normal function of the ALADIN protein.
 Even in the typical childhood occurrence  [1, 6, 7] of 
triple A syndrome, there is a risk of delayed diagnosis, as 
previously stated by other authors ( table 2 )  [4, 9–12] .   Due 
to paucisymptomatic manifestation during childhood 
and adolescence and the slow progression of the disease 
during adulthood, a delay in diagnosis may occur, as 
demonstrated by the reported case, with the clinical di-
agnosis postulated at 33 years and subsequently con-
firmed by genetic and biomolecular analyses. Adulthood 
may be a further confounding factor, the disease being 
generally diagnosed and managed by pediatricians, but 
in clinical practice, the disease should be taken into con-
sideration in adult patients with one or more clinical 
signs and symptoms of the disease  [4, 9–12] . Diagnosis of 
the disease is uncommon during adolescence and adult-
hood, and it is at a major risk of being overlooked and 
delayed, as in this case.
 Neurological disorders (autonomic failure and/or pe-
ripheral neuropathy, abnormal functioning of peripheral 
motor and sensory fibers), impaired cognitive functions, 
A B C D
E F G H
                  ------    ------   ------ 
Homo sapiens  546 aa NP_056480     WSSCCLRVFAWHPHTNKFAVALLDDSVRVYN
Pan troglodytes 519 aa XP_522403*  (100%/92%) WSSCCLRVFAWHPHTNKFAVALLDDSVRVYN
Bos taurus  495 aa XP_583023*  (100%/96%) WSSCCLRVFAWHPHTNKFAVALLDDSVRVYN
Canis familiaris  591 aa XP_849797*  (97%/94%)  WSSCCLRVFAWHPHTNKFAVALLDDSIRVYN
Mus musculus  546 aa NP_700465  (97%/94%)  WSSCCLRVFAWHPHTNKFAVALLDDSIRVYN
Rattus norvegicus 546 aa XP_001067255* (97%/92%)  WSSCCLRVFAWHPHTNKFAVALLDDSIRVYN
Gallus gallus     423 aa XP_423852*  (81%/56%)  WAGCSIRAFAWHPHTSKFAVALLDDSVRVYN
Xenopus laevis  523 aa AAH77988  (71%/64%)  WADCPLRAFAWHPHTYKFALALLDDSIRIYT
Danio rerio      499 aa NP_998390  (64%/56%)  WSDSAVRSFSWHPHTDKFAVALLDDSIKIYK
Tribolium castaneum 494 aa XP_969843*  (45%/33%)  WANNTIKCIAWHLHNSRLAVATCDDSVRIYC
Strongylocentrotus 472 aa XP_787398*  (45%/45%)  WQDSEIRAFAWHQHTNKCAVAWKDNTIKIFI
purpuratus
 Fig. 3. Species-specific sequence homology of the human arginine 167. Asterisks indicate a predicted or par-
tially predicted amino acid sequence. Amino acids in gray show differences in the species-specific ALADIN 
protein sequences compared to the human protein. The affected amino acid A167 is highlighted in bold face. 
Residues marked with – – – are predicted in humans to fold into   -sheets. Percentages demonstrate homology 
to the WD-Repeat motif and homology of the entire amino acid sequence compared to the human ALADIN 
protein. 
 Fig. 2. Cellular localization of the wild-type and Ala167Val mu-
tant ALADIN. While wild-type ALADIN is normally located to 
the nuclear pore complex ( E ), the mutant GFP-ALADIN A167V is 
mislocalized to the cytoplasm ( A , green).  B ,  F The localization of 
Nup62 (red).  C ,  G DAPI staining of the nucleus (blue).  D ,  H An 
overlay of figures  A–C and  E–G , respectively.  H Colocalization to 
the nuclear membrane (yellow).  D The lack of a yellow ring proves 
the absence of GFP-ALADIN A167V targeting at the nuclear pore 
complexes. The aberrant protein is mislocalized from the NPC to 
the cytoplasm in transfected HeLa cells as it happens when an 
ALADIN gene mutation is present  [13] . 
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mental retardation and dementia may all be part of the 
syndrome  [2, 6] . Several other concomitant features may 
involve different organ systems such as bone (premature 
osteoporosis), skin (palmoplantar hyperkeratosis, cutis 
anserina and impaired wound healing), and oral cavity 
(xerostomia and tongue abnormalities)  [2, 6] . Generally, 
alacrima is the first and most consistent symptom which 
can, however, be overlooked  [5] . Achalasia represents the 
most precocious symptom, which leads to medical con-
sultation not only in children  [5, 8] , but also in subjects 
with the late-onset disease ( table 2 )  [4, 9–12] .
 Adrenal insufficiency and neurological impairment 
can become clinically evident after a variable period of 
time ranging from 5 to more than 10 years after disease 
onset  [4, 9–12] ( table 2 ). As in the present case, neuro-
logical symptoms may progress slowly and the course of 
hypocortisolism may be subclinical, confirming that 
these disease features may be overlooked easily  [4, 9–12] . 
Autonomic dysfunction was present in one of the eight 
cases of late-onset triple A syndrome  [4] , but in the other 
subjects the symptoms (orthostatic hypotension and hy-
perhidrosis) provided cause for strong suspicion  [4, 9, 11, 
12] ( table 2 ).
 Severe hypoglycemic episodes due to hypocortisolism 
have been described  [6] in several previous reports and 
sudden deaths have been documented in triple A syn-
drome  [5–7] , as well as suggested by the family history of 
some affected subjects (i.e., probably unrecognized cases 
of affected relatives)  [11] . In fact, the onset of adrenocorti-
cal impairment usually occurs before puberty even though 
preservation of cortisol secretion into the third decade has 
been reported  [9] . Our patient never complained of symp-
toms related to severe hypoglycemia, but upon investiga-
tion, fasting glucose levels of less than 70 mg/dl were found 
relative to the several periods of hospitalization. This may 
have been due to subclinical adrenal insufficiency, present 
for several years before the diagnosis. The diagnosis of 
hypocortisolism is frequently delayed in patients with ad-
renal insufficiency, because of the subtle nature of the 
clinical complaints (weakness, tiredness, dizziness and 
slow weight loss) and several concomitant and confound-
ing features (e.g. malnutrition) as in this case. Such a delay 
in the diagnosis of adrenal insufficiency emphasizes the 
need for a correct assessment of the adrenal function in 
any young subject with achalasia or alacrima. In clinical 
practice, triple A-related adrenal insufficiency cannot be 
diagnosed only on the basis of the endocrine basal serum 
evaluation (ACTH and cortisol); it also requires dynamic 
tests  [14] , as in the investigation of the hypothalamic-pi-
tuitary adrenal axis in other clinical conditions  [15] .
 The patient’s clinical features should lead physicians 
to check the diagnosis of triple A syndrome, also in adult 
patients. The Schirmer test is a simple and reliable test for 
alacrima, but the diagnosis should be confirmed by ge-
netic analysis. Endocrinological evaluation should be 
based on both basal and dynamic measurements and hy-
pocortisolism should be periodically controlled as it may 
develop late in the disease. Metabolic, gastroenterological 
and neurological evaluations are mandatory to guarantee 
the patient’s wellbeing.
 Treatment and Management 
 Acquaintance with the disease could allow earlier di-
agnosis and therefore effective prevention of potentially 
life-threatening complications due to hypocortisolism in 
adult patients with suspected triple A syndrome. It seems 
that, as in children  [6] , also in these cases of late-onset 
triple A syndrome ( table 2 )  [1, 4, 9–12] adrenal insuffi-
ciency occurred after other clinical manifestations, and 
that it may be not have been present or may have been 
overlooked in evaluations performed some years before 
 [9] . In our patient, the diagnosis of adrenal insufficiency 
followed that of achalasia by about 20 years.
 After the endocrinological evaluation, replacement 
therapy with 37.5 mg/day cortisone acetate was initiated. 
Additionally, although no clear mineralocorticoid defi-
ciency was present, the patient was started on mineralo-
corticoid therapy (0.1 mg/day fludrocortisone acetate) in 
view of the symptomatic continuous hypotension, with 
subsequently markedly improved subjective feelings and 
blood pressure parameters.
 In order to improve the nutritional condition, both 
simple feeding suggestions (preference for ‘comminuted’ 
foods, frequent meals, soft or semi-liquid foods) and a 
diet of 2,090 kcal/day were provided. Iron, folate, vitamin 
B 12 , calcium and vitamin D 3 supplementation to the diet 
was strongly recommended. Treatment led to improved 
subjective feelings, blood pressure parameters and 
weight.
 Conclusions 
 We report the complex clinical course of a 33-year-old 
man with late-onset triple A syndrome, the diagnosis of 
which was delayed and the disease overlooked and un-
dermanaged probably as a consequence of its unusual 
manifestation in adulthood.
 As an increasing number of cases are being identified, 
the possible occurrence of triple A syndrome during 
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adulthood should be taken into consideration in clinical 
practice when one of the main signs or symptoms or more 
than one of the other symptoms are present, in order to 
avoid a delay in diagnosis and undermanagement of this 
rare form of the disease  [4, 9–12] ( table 2 ). Awareness of 
the possible late onset of the disease as well as the possi-
bility of a diagnosis in adulthood is still poor among en-
docrinologists, internists, gastroenterologists and neu-
rologists as previously suggested  [12] , the acquaintance 
with the disease remaining more common among pedia-
tricians. Thus, the diagnostic work-up carried out sug-
gests that the wide spectrum of clinical conditions re-
quires a multidisciplinary approach to the disease, espe-
cially in adulthood, involving different clinical skills for 
the diagnosis, the follow-up and the therapeutic deci-
sions. From this viewpoint, the follow-up should also in-
clude a periodical endocrinological evaluation by basal 
and dynamic testing.
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